WALTHAM, Mass., Apr 19, 2010 (BUSINESS WIRE) --Alkermes, Inc. (NASDAQ: ALKS) today announced that it will webcast its Research and Development (R&D) Day being held on Monday, April 26, 2010, at the Nasdaq MarketSite. The webcast will begin at 12:30 p.m. ET and will run until approximately 3:00 p.m. ET. At the meeting, members of the Alkermes team and a guest speaker will provide an update on the company's growing pipeline, proprietary platforms and overview the scientific rationale underlying its R&D strategy.
A live webcast of the event will be available on the investor relations section of the company's website at http://www.alkermes.com/. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled webcast. This webcast will be archived on the Alkermes website.
Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.
SOURCE: Alkermes, Inc.
Alkermes Contact:
Eva Stroynowski, 781-609-6823
Corporate Communications